The relationship of diuretics and dietary sodium in patients with heart failure: an analysis of the SODIUM-HF trial

IF 3.7 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS American heart journal Pub Date : 2024-12-04 DOI:10.1016/j.ahj.2024.11.019
Kevin Zhou MD , Wendimagegn Alemayehu PhD , Sarah Rathwell MSc , Finlay A. McAlister MD, MSc , Heather Ross MD, MHSc , Jorge Escobedo MD , Clara Saldarriaga MD , Eloisa Colin-Ramirez PhD , Peter Macdonald MD , Joanne Arcand PhD, RD , Richard Troughton MBChB , Justin A. Ezekowitz MBBCh, MSc , SODIUM-HF Investigators
{"title":"The relationship of diuretics and dietary sodium in patients with heart failure: an analysis of the SODIUM-HF trial","authors":"Kevin Zhou MD ,&nbsp;Wendimagegn Alemayehu PhD ,&nbsp;Sarah Rathwell MSc ,&nbsp;Finlay A. McAlister MD, MSc ,&nbsp;Heather Ross MD, MHSc ,&nbsp;Jorge Escobedo MD ,&nbsp;Clara Saldarriaga MD ,&nbsp;Eloisa Colin-Ramirez PhD ,&nbsp;Peter Macdonald MD ,&nbsp;Joanne Arcand PhD, RD ,&nbsp;Richard Troughton MBChB ,&nbsp;Justin A. Ezekowitz MBBCh, MSc ,&nbsp;SODIUM-HF Investigators","doi":"10.1016/j.ahj.2024.11.019","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>SODIUM-HF was a large clinical trial testing dietary sodium restriction compared to usual care in patients with heart failure that showed no reduction in clinical events. It has been suggested that diuretic doses in response to dietary sodium modification may have influenced the trial results.</div></div><div><h3>Objective</h3><div>We assessed the effects of baseline diuretic dose and diuretic dose changes on clinical outcomes in the SODIUM-HF trial.</div></div><div><h3>Methods</h3><div>Diuretics were converted to furosemide-equivalent diuretic total daily doses. Furosemide dose was treated as a continuous variable and also stratified into 0mg, 1mg to 39mg, 40mg, 41mg to 80mg, and &gt; 80mg daily. The baseline diuretic dose and change in diuretic dose were assessed and correlated with dietary sodium restriction and changes in dietary sodium intake. We then examined the relationship between diuretic dosing and the primary outcomes of SODIUM-HF (cardiovascular-related emergency department visit, cardiovascular-related hospitalization, and all-cause mortality).</div></div><div><h3>Results</h3><div>Of the 806 patients enrolled in the SODIUM-HF trial, 784 had known diuretic status at baseline: 209 patients (26.7%) with 0mg, 134 patients (17%) with 1mg to 39mg, 205 patients (26.1%) with 40mg, 118 patients (15.1%) with 41mg to 80mg, and 118 patients (15.1%) with &gt; 80mg. No correlation was found between dietary sodium intake and diuretic dose, either at baseline or change throughout the study (<em>P &gt; .</em>05). For the primary outcomes, the 2-year risk of primary outcomes was strongly correlated with diuretic dose at baseline across the overall SODIUM-HF population (<em>P &lt; .</em>001). No significant association was found between the treatment arm and the risk of primary outcomes, within each baseline diuretic dose range or with change in diuretic dose (both <em>P &gt; .</em>05).</div></div><div><h3>Conclusions</h3><div>Although a higher baseline diuretic dose was associated with worse clinical outcomes, no association was found between dietary sodium restriction, baseline or change in diuretic dose and the primary outcomes.</div></div>","PeriodicalId":7868,"journal":{"name":"American heart journal","volume":"281 ","pages":"Pages 49-58"},"PeriodicalIF":3.7000,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American heart journal","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0002870324003211","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Background

SODIUM-HF was a large clinical trial testing dietary sodium restriction compared to usual care in patients with heart failure that showed no reduction in clinical events. It has been suggested that diuretic doses in response to dietary sodium modification may have influenced the trial results.

Objective

We assessed the effects of baseline diuretic dose and diuretic dose changes on clinical outcomes in the SODIUM-HF trial.

Methods

Diuretics were converted to furosemide-equivalent diuretic total daily doses. Furosemide dose was treated as a continuous variable and also stratified into 0mg, 1mg to 39mg, 40mg, 41mg to 80mg, and > 80mg daily. The baseline diuretic dose and change in diuretic dose were assessed and correlated with dietary sodium restriction and changes in dietary sodium intake. We then examined the relationship between diuretic dosing and the primary outcomes of SODIUM-HF (cardiovascular-related emergency department visit, cardiovascular-related hospitalization, and all-cause mortality).

Results

Of the 806 patients enrolled in the SODIUM-HF trial, 784 had known diuretic status at baseline: 209 patients (26.7%) with 0mg, 134 patients (17%) with 1mg to 39mg, 205 patients (26.1%) with 40mg, 118 patients (15.1%) with 41mg to 80mg, and 118 patients (15.1%) with > 80mg. No correlation was found between dietary sodium intake and diuretic dose, either at baseline or change throughout the study (P > .05). For the primary outcomes, the 2-year risk of primary outcomes was strongly correlated with diuretic dose at baseline across the overall SODIUM-HF population (P < .001). No significant association was found between the treatment arm and the risk of primary outcomes, within each baseline diuretic dose range or with change in diuretic dose (both P > .05).

Conclusions

Although a higher baseline diuretic dose was associated with worse clinical outcomes, no association was found between dietary sodium restriction, baseline or change in diuretic dose and the primary outcomes.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
心力衰竭患者利尿剂与膳食钠的关系:钠- hf试验分析。
背景:钠- hf是一项大型临床试验,测试与常规护理相比,饮食钠限制对心力衰竭患者的临床事件没有减少。有人认为,利尿剂剂量对膳食钠修饰的响应可能影响了试验结果。目的:我们评估基线利尿剂剂量和利尿剂剂量变化对钠- hf试验临床结果的影响。方法:将利尿剂换算为相当于速尿的利尿剂总日剂量。速尿剂量作为连续变量处理,也分层为每日0 mg、1-39 mg、40 mg、41-80 mg和> -80 mg。评估利尿剂基线剂量和利尿剂剂量的变化,并将其与饮食钠限制和饮食钠摄入量的变化联系起来。然后,我们检查了利尿剂剂量与钠- hf主要结局(心血管相关急诊科就诊、心血管相关住院和全因死亡率)之间的关系。结果:在参加钠- hf试验的806名患者中,784名患者在基线时已知利尿状态:209名患者(26.7%)服用0 mg, 134名患者(17%)服用1-39 mg, 205名患者(26.1%)服用40 mg, 118名患者(15.1%)服用41-80 mg, 118名患者(15.1%)服用bbb80 mg。饮食钠摄入量与利尿剂剂量之间没有相关性,无论是在基线时还是在整个研究过程中都没有变化(P < 0.05)。对于主要结局,在整个钠- hf人群中,主要结局的2年风险与基线利尿剂剂量密切相关(P0.05)。结论:虽然较高的利尿剂基线剂量与较差的临床结果相关,但没有发现饮食钠限制、利尿剂基线剂量或利尿剂剂量变化与主要结果之间存在关联。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
American heart journal
American heart journal 医学-心血管系统
CiteScore
8.20
自引率
2.10%
发文量
214
审稿时长
38 days
期刊介绍: The American Heart Journal will consider for publication suitable articles on topics pertaining to the broad discipline of cardiovascular disease. Our goal is to provide the reader primary investigation, scholarly review, and opinion concerning the practice of cardiovascular medicine. We especially encourage submission of 3 types of reports that are not frequently seen in cardiovascular journals: negative clinical studies, reports on study designs, and studies involving the organization of medical care. The Journal does not accept individual case reports or original articles involving bench laboratory or animal research.
期刊最新文献
Design, rationale, and characterization of the Mobile health based OccuPational cardiovascular risk intErventioN study (mHealth-OPEN Study). Patient characteristics, presentation, causal microorganisms, and overall mortality in the NatIonal Danish endocarditis stUdieS (NIDUS) registry. Pharmaco-invasive Strategy and Dosing of Tenecteplase in STEMI Patients 60 to <75 Years: An Inter-trial Comparison of the STREAM-1 and STREAM-2 Trials: Comparison of Patients 60 to <75 Years in STREAM-1 and -2. Prospective randomized single-blind multicenter study to assess the safety and effectiveness of the SELUTION SLR 014 drug eluting balloon in the treatment of subjects with in-stent restenosis: rationale and design. Transcatheter or Surgical Aortic Valve Replacement in patients with Severe Aortic Stenosis Aged 70 Years or Younger - a NOTION-2 sub-study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1